SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced a clinical update regarding its proprietary anti-PSMA antibody drug conjugate (ADC) ARX517 ...
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results